

This article was downloaded by:

On: 27 January 2011

Access details: *Access Details: Free Access*

Publisher *Taylor & Francis*

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Nucleosides, Nucleotides and Nucleic Acids

Publication details, including instructions for authors and subscription information:

<http://www.informaworld.com/smpp/title~content=t713597286>

P₂-Purinoceptor Mediated Inhibition of Adenylate Cyclase Activity

A. M. Van Rhee^a; A. P. Ijzerman^a; W. Soudijn^a

^a Division of Medicinal Chemistry, Center for Bio-Pharmaceutical Sciences, RA Leiden, The Netherlands

To cite this Article Van Rhee, A. M. , Ijzerman, A. P. and Soudijn, W.(1991) 'P₂-Purinoceptor Mediated Inhibition of Adenylate Cyclase Activity', *Nucleosides, Nucleotides and Nucleic Acids*, 10: 5, 1239 — 1240

To link to this Article: DOI: 10.1080/07328319108047291

URL: <http://dx.doi.org/10.1080/07328319108047291>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.informaworld.com/terms-and-conditions-of-access.pdf>

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

P₂-PURINOCEPTOR MEDIATED INHIBITION OF ADENYLATE CYCLASE ACTIVITY

A.M. van Rhee*, A.P. IJzerman and W. Soudijn,
Division of Medicinal Chemistry, Center for Bio-Pharmaceutical Sciences,
P.O.Box 9502, 2300 RA Leiden, The Netherlands.

In 1972 Burnstock¹ proposed that adenosine 5'-triphosphate (ATP) is the principal neurotransmitter in non-adrenergic, non-cholinergic nerves through an interaction with P₂-purinergic receptors. In 1985 Burnstock and Kennedy² suggested a subdivision of this class of receptors into a P_{2x}- and a P_{2y}-subclass on the basis of rank order of potency of various ATP-analogues in pharmacological studies. The potency order on the P_{2x}-purinoceptor is α,β -methyleneATP (AMP.CPP) = β,γ -methyleneATP (AMP.PCP) > ATP = 2-methylthioATP (2MeSATP), whereas the potency order on the P_{2y}-purinoceptor is 2MeSATP >> ATP > AMP.CPP = AMP.PCP. Derivatization of ATP at various positions resulted in a more pronounced definition of the structure-activity requirements for both subtypes of the purinoceptor. The P_{2x}-purinoceptor is rather tolerant to modifications at the ribose moiety and the phosphate chain and the activity of adenine modified analogues is not affected. On the P_{2y}-purinoceptor the activity almost disappears when ribose-modified analogues are applied, but modification of the adenine ring results in enhancement, and modification of the phosphate chain results in a small decrease in activity.

Since most of the data is based on functional pharmacology, very little is known about signal transduction mechanisms and biochemical effects related to stimulation of these receptors. We investigated the possibility that one of the receptor subtypes is coupled to the second messenger system adenylate cyclase³. We found that various adenine nucleotides, either modified at the adenine ring, the

ribose moiety or the phosphate chain, inhibited forskolin-stimulated adenylate cyclase activity in membranes of rat hepatocytes, in a dose-dependent manner.

Since we used membranes, where the internal and external conditions are the same, and since ATP acts both as a neurotransmitter for the P_2 -purinoceptor and as a substrate for adenylate cyclase, we investigated the liability of these analogues to cyclization by adenylate cyclase. No such influence could be demonstrated except for two adenine nucleotides that demonstrated no inhibitory activity. Of the eight compounds used adenine-9 \rightarrow 1'-arabinofuranoside 5'-triphosphate (arabinoseATP) was the most active, with an IC_{50} -value of $26 \pm 3 \mu M$ and an availability as substrate relative to ATP of $0.2 \pm 0.2 \%$, whereas adenosine-5'-(2-O-thiodiphosphate) (ADP β S) stimulated the adenylate cyclase and had an availability as substrate of $32.1 \pm 3.7 \%$.

To exclude interference with adenylate cyclase we performed studies on intact cells as well. It was shown that in intact cells (viability $\geq 85\%$) adenylate cyclase could also be inhibited by adenine nucleotides in a dose-dependent manner. The most potent adenine nucleotides were ATP and ADP with an IC_{25} , i.e. the ligand concentration that inhibits maximal cAMP production by 25%, of $21 \pm 5 \mu M$ resp. $15.8 \mu M$. Generally, the potency of the nucleotides tested on whole cells appeared to be decreased by a factor 3 to 4 relative to the potency on membranes. Of the analogues tested the most potent was 3'-deoxyATP with an IC_{25} of $156 \pm 19 \mu M$.

From these data we conclude that the rank order of potency for purinoceptor mediated inhibition of adenylate cyclase does not fully match any of the functional pharmacological subclasses. Furthermore, considering the tolerance of the receptor to modifications at the ribose moiety we suggest that the P_2 -purinoceptor coupled to adenylate cyclase in the rat hepatocyte resembles the $P_{2\alpha}$ -subtype.

REFERENCES

1. Burnstock, G., 1972, *Pharmacol. Rev.* 24, 509.
2. Burnstock, G., Kennedy, C., 1985, *Gen. Pharmacol.* 16, 433.
3. Okajima, F., Tokumitsu, Y., Kondo, Y., Ui, M., 1987, *J. B. C.* 262, 13483.